Author

Josep Tarragó‐Celada

The Francis Crick InstituteORCID 0000-0001-7322-9736Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

Mariia O. YunevaiD· 2 shared Alejandro Suárez‐BonnetiD· 1 shared Asad Mahmood· 1 shared Carles FoguetiD· 1 shared Claudia Hernández-Carro· 1 shared Erika ZoddaiD· 1 shared Ersa GjelajiD· 1 shared Ibrahim H. PolatiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Mariia O. YunevaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 19, 2026

Histidine exchange sustains LAT1 activity and proliferation in glutamine-addicted breast cancers.

Ersa Gjelaj, Paul C. Driscoll, Asad Mahmood…·Mariia O. Yuneva

The paper identifies histidine as a key substrate for LAT1 that supports mTORC1 signaling and proliferation in glutamine-addicted breast cancers, revealing a metabolic vulnerability.

DOI 10.64898/2026.04.15.716193

humanproteomics

𝕏 PostBluesky

Cancer BiologyOncogenePeer-reviewedJul 22, 2025

Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells

Míriam Tarrado‐Castellarnau, Carles Foguet, Josep Tarragó‐Celada…·Marta Cascante

This study shows that combining Palbociclib with Telaglenestat prevents acquired resistance in colorectal cancer cells by counteracting metabolic reprogramming.

12 citations

humanmetabolomics

𝕏 PostBluesky